Heart failure (HF) is a major global problem 1 . Studies have helped in understanding this clinical entity and define areas where the quality of care is deficient [2] [3] [4] [5] . The paucity of data outside of North America and Europe is the main challenge 6 . Shortcomings and barriers to the implementation of evidencebased therapy could not be analyzed without defining these types of gaps in knowledge.
< 60 ml/min, history of coronary artery disease (CAD) and atrial fibrillation (Afib), causes of decompensation, basic hemodynamic parameters (admission heart rate (HR) and blood pressure (BP)), hemoglobin and creatinine level, left ventricle ejection fraction (LVEF), medications, length of stay and inhospital mortality. Upon discharge, basic hemodynamics (discharge HR and BP) and medications were documented. Compliance to medications was verified by reviewing the chart, follow-up visits, and central hospital pharmacy dispensary desk information. During the follow-up period, only some of the HHF patients were seen. Within each hospitalization, the same variables were traced. Ethical approval of the institute was obtained.
Statistical Analysis
P-value of <0.05 was considered significant. Frequencies, as well as differences between groups, were analyzed using Pearson's chi-squared test or Fisher's exact test. The analysis was done using Student's t-test. Multivariable logistic regression (MLR) was performed to determine the predictors of readmission with heart failure and in-hospital mortality.
RESULT
The mean age was 64.5+13.5 years. One hundred seventy (69%) patients were male. HTN was the most common comorbidity, 179 (73%), followed by hyperlipidemia, 166 (68%), and DM, 161 (64%). CAD was seen in more than half of the patients, 127 (52%), more than one-third had renal impairment, 80 (33%) and one-fifth had Afib, 54 (22%). Twenty-four (10%) patients sustained a stroke, see table 1. The mean left ventricular ejection fraction (EF) was 34% (HF with reduced EF 60%, HF with preserved EF 16 %, and HF with midrange EF 24%), see figure 1.
Precipitating Causes of Decompensation
The causes of decompensation were as follows: non-defined, non-adherence to medications, myocardial ischemia and hypertensive crisis, see table 2.
Systolic BP (SBP), diastolic BP (DBP) and HR were 155+42 mmHg, 89+22, and 101+24 beats per min (bpm), respectively. At discharge, SBP, DBP, and HR were 127 mmHg, 71 mmHg and 71 bpm, respectively; see figure 2.
All patients were admitted to the CCU. The average hospital stay was seven days, see figure 3 . The mean hemoglobin was 12 g/dl and serum creatinine was 120 mmol/L, see table 1. Two-hundred-forty (98%) patients received intravenous loop 
DISCUSSION
The mean age was 65+14 years, which was similar to other studies in developing countries 6 . Patients in heart failure studies in North America, Europe, and Japan tended to be older [2] [3] [4] [5] . The regional age variation is well-known and can be partially explained by the prevalence of underlying risk factors in different societies. Precipitating causes for decompensation for heart failure could reflect underlying etiology. Myocardial Ischemia represented 21% of the incidents, much less than reported in other studies [2] [3] [4] [5] . Administration of therapeutic heparin in 63% of the patients could indicate that myocardial ischemia is under-reported. Comorbidities can increase the risk of myocardial ischemia in this population. Underutilization of coronary angiograms and non-invasive workups (such as coronary computed tomography angiogram or dobutamine echocardiogram) for myocardial ischemia during the initial admission might explain our findings.
In our study, HTN triggered 16% of the acute heart failure episodes. HHF is a common presentation of hypertensive crisis in Bahrain 8, 9 . DM was seen in 64% of patients. Across the spectrum of cardiovascular diseases, diabetes amplifies the risk and worsens the prognosis 10, 11 . More than 50% of the patients had CAD. We found CAD to be an independent readmission predictor for HF. One-fifth of the patients had Afib reflecting the high prevalence of systemic HTN in the cohort. Renal impairment was seen in 33%. Adding to its prognostic implication, initiation, and increase in evidence-based therapy could be limited in the presence of impaired renal function 12 .
BP at initial presentation in our study was the highest compared to other studies. The mean LVEF was 34.4+14 SD with the majority being HF with reduced ejection fraction (HFREF). Patients with HF of mid-range EF (HFMEF) comprised 26%; such category might represent an intermediate stage in the remodeling process of hypertensive heart diseases. The outcome of this group is to be verified by further clinical research 13 .
Other than MRA, the rate of adherence to evidence-based therapy is observed in the majority of patients. Because 33% have renal impairment, the risk of hyperkalemia is a concern when using RAS blockers or MRA. In-hospital initiation of beta-blockers and angiotensin converting enzyme inhibitors (ACE-I) is an important predictor for long-term compliance for both and should be advocated [14] [15] [16] [17] .
The median length of stay was seven days, and in-hospital mortality was 9.4%. In other studies, the median length of stay ranges from 4 to 28 days and in-hospital mortality from 4% to 30% 1 . Twenty-four (10%) were mechanically ventilated. The rate of renin-angiotensin system (RAS) blockers, beta-blockers and mineralocorticoid receptor antagonist (MRA) had increased at discharge compared to the rate at initial hospitalization. The rest of the medications are shown in table 3.
The mortality rate was 9.4%. There was a significant association between in-hospital mortality and the following factors: age, HR at admission >100 bpm, length of stay, evidence of stroke, CAD, renal impairment, and elevated serum creatinine. Receiving an angiotensin receptor blocker (ARB) at admission was negatively associated with in-hospital mortality, see figure 4 . We found a median length of stay beyond seven days to be closely related to in-hospital mortality 1 . Studies with lower hospital stay have lower mortality 1 . Variables of mortality, such as age, HR >100 bpm at admission, CAD, and non-cardiac morbidities are similar to other studies [18] [19] [20] [21] [22] [23] [24] . Our findings of reduced mortality with prior ARB therapy was similar to a study from Japan 4 . Readmission predictors in our study were as follow: HR of ≥78 bpm at discharge, DM and CAD. Predicting readmission is more challenging than predicting mortality due to HHF.
Readmission with Heart Failure
The limitation of this study was the small size sample. Bahrain has 1.2 million inhabitants. With an estimated heart failure prevalence of 2.5%, the total number of patients in Bahrain with this disease would be approximately 30,000. A sample of 245 patients has a 95% confidence level and 6.24 CI representative ability. In addition, the quality of documentation needs to be improved.
CONCLUSION
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